TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Proportion of patients with pH > 6 for more than 60% of the time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 5-year local recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Children's Hospital of Eastern Ontario Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of POAG
Endpoint domain: Mortality/survival
Primary endpoint: One-year Probability of Survival
Endpoint domain: Mortality/survival
Primary endpoint: Plaque reduction rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28-CRP scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RAMRIS synovitis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NYHA class I or II at six months postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective orifice area (EOA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: residual glomerular filtration rate (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Major non-coronary artery bypass surgery-related bleeding at 96 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Ischemia as detected by continuous ECG evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Death or myocardial infarction at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Referral for colposcopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with skeletal events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regular filter usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quality of water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation exposure to the thyroid/eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation exposure to the chest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation exposure to the hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RBC transfusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean concentration of bimatoprost acid in aqueous samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean concentration of latanoprost acid in aqueous samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: left ventricular hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Kansas City Cardiomyopathy Questionnaire scores at 30 days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Request for rescue analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: PONV scores
Endpoint domain: Adverse events/effects
Primary endpoint: Extubation rate by day 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mortality by day 28
Endpoint domain: Mortality/survival
Primary endpoint: Serum total cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minor hypoglycaemia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Hepatic and muscle protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: No restrictions on engaging in valued activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Shorter time to return to normal activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Few or no side effects from antibiotics
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in LV end-diastolic volume (LVEDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite endpoint of death or recurrent myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: HBV DNA undetectable
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hypercalciuria
Endpoint domain: Adverse events/effects
Primary endpoint: KCCQ scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Circulating BDNF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year risk for death, reinfarction, or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Good effect duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acetylcholine-induced vasodilatation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: L-NMMA response improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of abdominal CT scans obtained
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: active participation in the intervention
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Referral sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Negative predictive value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of malignant skin tumors missed
Endpoint domain: Adverse events/effects
Primary endpoint: post‐bronchodilator therapy FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Quit rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: whole-body aBMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: leg BMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: postural balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvements in neuropathic pain-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global health status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fibrinogen level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: maximum change in ACh mediated FBF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: urinary LTE(4) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL cholesterol:HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PASI 75 response achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median blood loss after delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: decrease in skin roughness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Lens nuclear back scattering
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free survival
Endpoint domain: Physiological/clinical
Primary endpoint: comfortable separation from parents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: restful IV catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recall of pre-anesthetic events
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Relief of hot-flushes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total tryptophan levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Free tryptophan concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of amniotic fluid infection or lung maturity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of attempts at straightening the colonoscope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of looping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total doses of midazolam administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic Blood Pressure (SBP) changes during tracheal extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Rate (HR) changes during tracheal extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 5-year survival proportions
Endpoint domain: Mortality/survival
Primary endpoint: overall death risk
Endpoint domain: Mortality/survival
Primary endpoint: BC-specific death risk
Endpoint domain: Mortality/survival
Primary endpoint: Little's Irregularity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Available space for the mandibular incisors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost per point reduction on the Beck depression inventory-II
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: MMP-2 transcript levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leptin levels in serum and milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior-posterior head angular sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trunk sway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in knowledge with training
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-rated competence in management of chronic pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with managing chronic pain care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall sexual functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: postoperative outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean peak pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Depression scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ADR reporting rate increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total OLS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OLS-PI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 50% reduction in OLS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cutting capacity of carbide burs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to feed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who improved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic effect (neuroleptic minus placebo)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-emergent side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Total daily insulin dose (U/kg/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Standard deviation of glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of hyperuricemia
Endpoint domain: Mortality/survival
Primary endpoint: Reversion of hyperuricemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfactory hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total anastomotic time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sirolimus AUC and trough levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: self-efficacy to implement health-promoting behaviours
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: angina stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: exclusive breastfeeding at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: full breastfeeding at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ovarian hyperstimulation syndrome (OHSS) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Patient and nurse acceptance of follitropin alfa pen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intragastric pH > 4 maintained duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: FS recurrence
Endpoint domain: Mortality/survival
Primary endpoint: 6-month post-quit abstinence
Endpoint domain: Mortality/survival
Primary endpoint: lipomembranous changes of the fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: epidermal damage
Endpoint domain: Adverse events/effects
Primary endpoint: Sleep problems index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: FACT Fatigue change score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Virological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma L‐hArg concentration increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCs0‐24h of L‐hArg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of L‐hArg
Endpoint domain: Adverse events/effects
Primary endpoint: Median time to development of CNS metastases
Endpoint domain: Mortality/survival
Primary endpoint: Bilateral presenting acuity worse than 20/40
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best-corrected acuity worse than 20/40
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual impairment or blindness rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall success rate of medical treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone height (HAB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resonance frequency (RSV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival at day 60
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in CTP scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in MELD scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean NPRS score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite cardiovascular endpoint (death, myocardial infarction, congestive heart failure, arrhythmia)
Endpoint domain: Mortality/survival
Primary endpoint: Potency of ropivacaine compared to bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically important benefit from digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability and validity of the DOS-ES questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean stone size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for narcotic medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cost of anesthetic drugs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AASI (Aortic Augmentation Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area of anhidrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall in peak expiratory flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: overall subject satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: functional gain (250‐6000 Hz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sound quality of speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of moderate-to-severe hot flashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serious post-operative complications rate
Endpoint domain: Adverse events/effects
Primary endpoint: cumulative occurrence of variceal status and ascites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR 20 standard-reaching rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR 50 standard-reaching rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-density lipoprotein (LDL) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Costs per case
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Productivity losses
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Postoperative Delirium (POD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: height-for-age z scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean plasma propofol concentrations at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean plasma remifentanil concentrations at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neonatal Apgar scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erectile function restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of mental health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gastroduodenal ulcer occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Cardiovascular events occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of the efficacy endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dyspepsia improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Absolute bioavailability of rivastigmine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion rates for HPV-16/18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean antibody titers (GMTs) for HPV-16/18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-HBs seroprotection rates for hepatitis B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: clearance rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DeltaSa (change in Sa during dobutamine infusion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: increase of breast density change in the Wolfe classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Seroconversion at 6 months post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increases in serum antibody levels at 3 and 6 months post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: VZV vaccine-related adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: mean change in CAT score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients receiving guideline inconsistent imaging referrals (GICI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient decisional conflict
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Worsening of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neopterin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma kynurenine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cerebral desaturation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rSO2 value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in physical performance battery score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grip strength decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in 2-minute walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical anxiety scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes